The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

India 10-year bond yield fell 0.41 per cent to 5.89 after trading in 5.87-5.91 range NEW DELHI: The Nifty Pharma index traded ...

Rajeev Juneja, vice chairman and managing director of Mumbai, Indian-based drugmaker Mankind Pharma (NSE: MANKIND), today ...

Mankind Pharma has launched generic versions of diabetes medication Empagliflozin under brand names Empaglyde, Empagreat, and ...

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

Mankind Pharma has launched a generic version of Empagliflozin in India under the brands Empaglyde, Empagreat, and Dynaduo. The launch breaks cost barriers, offering the medication at competitive ...

The Nifty Pharma index closed on a positive note on Tuesday. Shares of J B Chemicals & Pharmaceuticals Ltd.(up 4.48 per cent) ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.